Skip to content
ALS News Today logo Newsletter
Newsletter
  • About ALS
    What is ALS?
    Causes and risk factors
    Diagnosis
    Symptoms
    • Speech problems
    • Breathing and swallowing
    • Pseudobulbar affect
    Types of ALS
    • Familial ALS
    • Sporadic ALS
    Living with ALS
    • Mental health
    • Diet
    • Exercise
    • Aids and adaptations
  • Treatments
    Approved treatments
    Experimental treatments
    Non-drug treatments
  • News
  • Columns
    Joyful Sorrow — Kristin Neva
    Living Well With ALS — Dagmar Munn
    Thunder Road — Juliet Taylor
    Archived columns
    • OutSpoken — James Clingman
    • The Mighty Mind — Rachel Doboga
    In memoriam
    • Notes From the ALS Front — Rick Jobus
  • Forums
  • Advocacy partners
  • What can we help you find today?

June 28, 2023 News by Patricia Inácio, PhD

FNP122, edaravone in oral form, enters Phase 3 extension trial

A Phase 3 clinical trial that’s testing FNP122, Ferrer’s oral formulation of edaravone, in people with amyotrophic lateral sclerosis (ALS) is now rolling participants into its open-label extension study. The ADORE trial (NCT05178810) is testing FNP122 against a placebo in about 300 patients across Europe whose…

November 15, 2021 News by Patricia Inácio, PhD

Phase 3 Trial of FNP122, Oral Form of Edaravone, Starts Enrolling in Europe

A first patient has been enrolled in a Phase 3 clinical trial investigating FNP122, an oral formulation of edaravone being developed by Ferrer to treat amyotrophic lateral sclerosis (ALS). The ADORE trial aims to enroll 300 patients across Europe to assess the safety and efficacy of FNP122, as well as its…

Recent Posts

  • Dazucorilant significantly extends survival in Phase 2 ALS trial
  • Brain-computer interface allows man with ALS to talk in real time
  • What I can’t accept about ALS, despite years of processing it
  • Bipartisan congressional effort calls for increased ALS research funding
  • Finding comfort in AI: Using ChatGPT to cope with ALS grief


Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: info@bionews.com
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.